These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1043 related items for PubMed ID: 22409231

  • 1. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
    Stopeck A, Rader M, Henry D, Danese M, Halperin M, Cong Z, Qian Y, Dansey R, Chung K.
    J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
    [Abstract] [Full Text] [Related]

  • 2. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis.
    Snedecor SJ, Carter JA, Kaura S, Botteman MF.
    J Med Econ; 2013; 16(1):19-29. PubMed ID: 22870908
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer.
    Snedecor SJ, Carter JA, Kaura S, Botteman MF.
    Clin Ther; 2012 Jun; 34(6):1334-49. PubMed ID: 22578308
    [Abstract] [Full Text] [Related]

  • 5. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
    Xie J, Namjoshi M, Wu EQ, Parikh K, Diener M, Yu AP, Guo A, Culver KW.
    J Manag Care Pharm; 2011 Oct; 17(8):621-43. PubMed ID: 21942303
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
    Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H.
    J Clin Oncol; 2011 Mar 20; 29(9):1125-32. PubMed ID: 21343556
    [Abstract] [Full Text] [Related]

  • 9. Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).
    Shapiro CL, Moriarty JP, Dusetzina S, Himelstein AL, Foster JC, Grubbs SS, Novotny PJ, Borah BJ.
    J Clin Oncol; 2017 Dec 10; 35(35):3949-3955. PubMed ID: 29023215
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
    De Cock E, Hutton J, Canney P, Body JJ, Barrett-Lee P, Neary MP, Lewis G.
    Clin Ther; 2005 Aug 10; 27(8):1295-310. PubMed ID: 16199254
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
    Stopeck A, Brufsky A, Kennedy L, Bhatta S, Bhowmik D, Buchanan J, Despiegel N, Hechmati G.
    J Med Econ; 2020 Jan 10; 23(1):37-47. PubMed ID: 31364885
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cost effectiveness of zoledronic acid in the management of skeletal metastases in hormone-refractory prostate cancer patients in France, Germany, Portugal, and the Netherlands.
    Carter JA, Joshi A, Kaura S, Botteman MF.
    J Med Econ; 2011 Jan 10; 14(3):288-98. PubMed ID: 21469915
    [Abstract] [Full Text] [Related]

  • 18. Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours.
    Ford J, Cummins E, Sharma P, Elders A, Stewart F, Johnston R, Royle P, Jones R, Mulatero C, Todd R, Mowatt G.
    Health Technol Assess; 2013 Jul 10; 17(29):1-386. PubMed ID: 23870108
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.